Transfusion Medicine (TRANSFUSION MED )

Publisher: British Blood Transfusion Society, Blackwell Publishing


An international journal published for the British Blood Transfusion Society. Transfusion Medicine reflects the interests of clinicians, scientists and other professionals working in the broad field of blood transfusion medicine.The Journal publishes original articles and reviews by international experts in the field - rapid publication is a high priority. Transfusion Medicine also features invited reviews, state-of-the-art reports, good practice guidelines, leading articles, Letters to the Editor, occasional historical articles and signed book reviews. Abstracts of science meetings and the proceedings of symposia (in supplement form) are also published from time to time.

  • Impact factor
    Show impact factor history
    Impact factor
  • 5-year impact
  • Cited half-life
  • Immediacy index
  • Eigenfactor
  • Article influence
  • Website
    Transfusion Medicine website
  • Other titles
    Transfusion medicine (Oxford, England)
  • ISSN
  • OCLC
  • Material type
    Periodical, Internet resource
  • Document type
    Journal / Magazine / Newspaper, Internet Resource

Publisher details

Blackwell Publishing

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • Some journals impose embargoes typically of 6 or 12 months, occasionally of 24 months
    • no listing of affected journals available as yet
  • Conditions
    • See Wiley-Blackwell entry for articles after February 2007
    • Publisher's version/PDF cannot be used
    • On author's server, institutional server or subject-based server
    • Server must be non-commercial
    • Publisher copyright and source must be acknowledged with set statement ("The definitive version is available at")
    • Articles in some journals can be made Open Access on payment of additional charge
    • 'Blackwell Publishing' is an imprint of 'Wiley'
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Platelet transfusions are used in clinical practice to prevent and treat haemorrhage in thrombocytopenic patients or patients with severe platelet dysfunction. In the UK, and abroad there has been a recent rise in platelet component demand. The three largest patient groups that use platelet components are patients with haematological malignancies (up to 67%), patients receiving cardiac surgery (up to 10%) and patients receiving intensive care (up to 8%). This review has explored some of the factors that may explain this recent trend within these three main groups. These factors include a rise in the general population, an ageing population, an increase in the incidence and prevalence of haematological malignancies, and changes in the management of patients with haematological malignancies. However, the only data available that can be correlated directly with national component data are the size of the total population. There is no evidence to support the premise that use of platelet components in patients receiving cardiac surgery or intensive care treatment is rising over and above the general rise in the population, but the data are sparse.
    Transfusion Medicine 10/2014; 24(5):260-8.
  • Transfusion Medicine 10/2014; 24(5):257-9.
  • Transfusion Medicine 06/2014; 24(3):189-90.
  • Transfusion Medicine 02/2014; 2014(Febr).
  • Source
    Transfusion Medicine 01/2014; 24(1).
  • Transfusion Medicine 10/2013; 23(5).
  • Transfusion Medicine 01/2013; XX.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Using population prevalence data for deferrable diseases/conditions we estimated the Canadian population eligible to donate according to three upper‐age limit scenarios. Background The donor selection criteria limit the number of potential blood donors but relaxing the upper age criteria could mitigate this. Methods and MaterialsForty deferral criteria were identified and their corresponding prevalence data obtained to estimate the number of people excluded by the criteria. The eligible blood donor population was estimated from national census data taking the age limits, deferral criteria and deferral time‐period into account. As more than one disease/condition may co‐exist, the estimate was adjusted to avoid over‐representation. ResultsOf about 33 million Canadians aged 17 (18 in Québec) to 65, 15·1 million (45·8%) are eligible to donate blood. This number increases to 15·7 million when including people up to 71 years and to 17·1 million in the absence of an upper age limit. Conclusion As about 1·2 million units are collected from 600 000 donors annually, there are more than enough eligible people to meet the need. However, recruitment of donors is challenging and the absence of an upper age limit allows an additional 2 million people to donate. Other countries may wish to consider modification of the upper age criterion to address the effect of an aging population on the blood supply.
    Transfusion Medicine 01/2012; 22(6).
  • Transfusion Medicine 01/2008; 17(6):488-90.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective was to study the gene frequencies of HPA-1 in the Lebanese population for the first time. The aims of this study were to assess the prevalence of 1a and 1b HPA-1 alleles in healthy Lebanese individuals and compare with the international literature. Human platelet antigen (HPA) systems are involved in alloimmunization, organ transplantation rejection and the development of cardiovascular disease. Of several classified HPA systems, HPA-1 specifically has been considered to be the most important antigenic system implicated in the Caucasian population. This specific gene has never been investigated in our population. DNA was extracted from specimens collected from 205 healthy unrelated Lebanese individuals and tested, using a reverse hybridization polymerase chain reaction (PCR) assay, for the prevalence of 1a and 1b HPA-1 alleles. Genotypes 1a/1a, 1a/1b, and 1b/1b were assigned accordingly. We observed that the 1a/1a genotype was the most prevalent (65.85%) followed by 1a/1b (30.24%) and 1b/1b (3.91%) with allelic frequencies for 1a and 1b of 0.81 and 0.19, respectively. As compared with other ethnic groups, the Lebanese population was found to have a relatively high prevalence of the HPA-1b, which may predispose to a higher risk of alloimmunization. This report is the first to study the prevalence of the HPA-1 system in the Lebanese population and serves as a template for future clinical research involving platelet disorders and cardiovascular diseases.
    Transfusion Medicine 01/2008; 17(6):473-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In 1975, the World Health Assembly recommended that blood for transfusion should come from voluntary, non-remunerated donors; yet, in Africa, 75-80% of blood for transfusion still comes from hospital-based replacement donors. Although comprehensive economic data are scarce, evidence indicates that blood from voluntary donors recruited and screened at centralized transfusion centres, costs four to eight times as much as blood from a hospital-based, replacement donor system. Donor recruitment, quality assurance systems and distribution mechanisms in the centralized system are major reasons for the cost difference. There are concerns about the sustainability of centralized voluntary donor systems and their compatibility with the levels of health care that exist in many poor countries yet burdening patients' families with the responsibility of finding replacement blood donors will exacerbate poverty and reduce the safety of the blood supply. There are measures that can be introduced into hospital-based systems to improve safe blood supply in Africa but their effectiveness in different contexts needs to be evaluated.
    Transfusion Medicine 01/2008; 17(6):434-42.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Donations in Greece are insufficient to cover the high transfusion needs arising from large numbers of thalassaemia and sickle cell anaemia patients and the implementation of new surgical techniques. Efforts to achieve self-sufficiency, and to render blood supplies safer and manageable must focus on recruiting and retaining more volunteer donors and on converting the large pool of replacement donors. The aim of the study was to gain insight into public perception regarding the risks of donation and transfusion and to identify the factors that would motivate more people in Greece to regularly donate blood. Questionnaires were distributed to 1,600 donors at the blood bank and visitors to hospitals at 11 locations across the country. Data on demographics, donation behaviour, incentives, risk perception and attitudes towards donation and transfusion were analysed separately for volunteer and replacement donors and non-donors. The results showed that women and young people donate the least in Greece. Also, many donors do not donate because they are not reminded to. A small percentage of donors confessed to having concealed part of the truth to background questions. Overall, incentives to donate were considered important and included future availability of blood for self or family, paid leave from work and free blood tests. Recruitment and retention efforts should include better communication with current donors, and raising awareness among eligible donors. Staff should be educated in soliciting information from potential donors, and incentives should be better aligned to avoid conflict with ethical values and ensure honesty in the prescreening process.
    Transfusion Medicine 01/2008; 17(6):443-50.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Extension of the QT interval is characterized by syncope and cardiac arrest and often occurs in association with medical therapies and procedures. Whether erythroapheresis (EPH) could influence the QT interval duration in patients with sickle cell disease (SCD) is not known. We aimed to investigate the effects of EPH on the heart rate-corrected QT (QTc) interval. The study included 25 patients with SCD who underwent 34 EPH procedures. Two independent observers measured QTc interval duration from electrocardiograms performed continuously for 3 min at three different points during the EPH procedures (prior to EPH, after completion of 50% EPH and 15 min after EPH). Multiple regression analysis was used to determine if the ionized plasma calcium, the level of plasma magnesium, citrate infusion rate and painful crisis significantly contributed to the QTc interval. There was a non-significant trend (P = 0.184) towards increased QTc in sickle cell patients during EPH compared with pre-EPH values. QTc prolongation (>440 ms) occurred in 72% of the procedures. Fifty percent QTc values returned to baseline after the procedure. The independent variables were not significantly associated with QTc interval. Exchange procedures can induce QTc prolongation in patients with SCD.
    Transfusion Medicine 01/2008; 17(6):466-72.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To examine the accuracy, feasibility and benefits of screening for hepatitis C virus core antigen (HCVAg) using enzyme-linked immunosorbent assay (ELISA) test in pools. Many countries cannot afford to test blood donations for hepatitis C using molecular methods. Screening individual units using the ELISA HCVAg test is an acceptable, yet still expensive, alternative, especially for small blood bank settings. This study evaluated the option of screening for HCVAg in pools. The sensitivity (Se) and specificity (Sp) of HCVAg in pools of three and six antibody-negative samples were estimated and compared with polymerase chain reaction (PCR). The feasibility and cost-benefit of the assay was assessed on 960 routine samples collected at a hospital blood bank in Gaza. Based on results for 50 PCR-positive pools and 50 and 110 PCR-negative pools of three and six, the Se of testing in pools of three and six samples is 80-82% [95% confidence interval (CI): 66.3-91.4] and Sp >or=98% (95% CI: 89.4-100.0) compared with PCR. The incidence of antigen in donors in Gaza was 0.1% (95% CI: 0-0.56). Cost analyses suggested significant benefits from implementing screening blood donations for HCVAg when the incidence rate is >4.2/10,000, leading to reduction in the expenditures needed to treat patients infected with HCV. The risk of transfusion-transmitted hepatitis C in resource-deprived developing countries can be efficiently reduced by additional screening of antibody-negative blood donations for HCVAg in pools of six.
    Transfusion Medicine 12/2007; 17(6):479-87.
  • Transfusion Medicine 11/2007; 17(5):413-4.
  • Transfusion Medicine 11/2007; 17(5):353; discussion 366.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Determination of fetomaternal haemorrhage (FMH) remains an area of difficulty. In most cases, prophylactic Rh immunoglobulin is usually administered to affected women without testing for foetal red blood cells (RBC). Here, we describe a new particle gel immunoassay (PaGIA) for the determination FMH (FMH-PaGIA). Superparamagnetic particles were coated with monoclonal anti-D and mixed with ethylenediaminetetraacetic acid-anticoagulated blood samples from D-negative pregnant women. The particles were isolated using a magnetic particle concentrator and then placed into the reaction chamber of a gel card. Agglutinated particles on top or dispersed through the gel matrix indicated the presence of D-positive cells. After the test was adapted to detect >or=0.3% D-positive RBC, randomly selected postpartum samples from 208 women were analysed in parallel with the Kleihauer-Betke test (KBT). In addition, all discrepancies were further analysed by flow cytometry. A total of 203 of the 208 postpartum samples were negative in both tests. One sample reacted positive with both assays. Two samples were strongly positive in the new FMH-PaGIA, but negative in the KBT. A serological re-examination revealed that both women were D positive. The KBT gave a false-positive result in two cases because of hereditary persistence of haemoglobin F. The new test is specific, easy to perform and can be done at any time in all laboratories.
    Transfusion Medicine 11/2007; 17(5):395-8.